Aurinia Pharmaceuticals Inc. (AUPH)
$16.55-0.60%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 1.41
- P/E (TTM)
- 6.65
- Short % float
- 6.27%
- Days to cover
- 9.4
- SI change
- -7.7%
- 1W
- +5.28%
- 1M
- +2.80%
- vs SPY 1W
- +4.86%
- vs SPY 1M
- +0.73%
Industry peers
FMP comparable companies · ranked by market cap
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 20$29.42-7.23%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-2.24%
- TRAXSELLFirst Tracks Biotherapeutics Inc$1.1BQ 85$31.39+6.91%
- MLTXSELLMoonLake Immunotherapeutics$921MCRISISQ -0$10.95-1.29%
- ALMSSELLAlumis Inc.$855MCRISISQ 1$6.93-1.40%
- ATTOSELLAttovia Therapeutics, Inc.$753MQ -47$17.50-9.99%
- ACRSSELLAclaris Therapeutics, Inc.$517MCRISISQ 9$3.70-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AUPH?
- LOPJLB’s latest quantitative signal on Aurinia Pharmaceuticals Inc. (AUPH) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AUPH in?
- Aurinia Pharmaceuticals Inc. (AUPH) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aurinia Pharmaceuticals Inc. (AUPH) do?
- Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an appro…